Compare · CBUS vs NXTS
CBUS vs NXTS
Side-by-side comparison of Cibus Inc. (CBUS) and Nexentis Technologies Inc. (NXTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBUS and NXTS operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CBUS is the larger of the two at $93.9M, about 25.0x NXTS ($3.8M).
- Over the past year, CBUS is down 26.5% and NXTS is down 92.4% - CBUS leads by 65.9 points.
- CBUS has been more active in the news (12 items in the past 4 weeks vs 2 for NXTS).
- CBUS has more recent analyst coverage (4 ratings vs 0 for NXTS).
PerformanceCBUS-25.15%NXTS-92.40%
2025-06-10+0.00%2026-06-08
- Company
- Cibus Inc.
- Nexentis Technologies Inc.
- Price
- $1.22-5.06%
- $5.38-15.01%
- Market cap
- $93.9M
- $3.8M
- 1M return
- -19.74%
- +16.70%
- 1Y return
- -26.51%
- -92.40%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 12
- 2
- Recent ratings
- 4
- 0
Latest CBUS
- Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation
- Cibus Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Finn Mark Terrence
- SEC Form 4 filed by Director Moretti August J
- SEC Form 4 filed by Director Riggs Rory B
- Director Prante Gerhard was granted 64,748 shares, increasing direct ownership by 161% to 104,945 units (SEC Form 4)
- Director Lehmann Jean-Pierre Jules was granted 64,748 shares, increasing direct ownership by 9% to 763,904 units (SEC Form 4)
- SEC Form 4 filed by Director Box Kimberly Ann
- SEC Form 4 filed by Director Wichner Craig
- Director Urban Thomas was granted 64,748 shares (SEC Form 4)
Latest NXTS
- Nexentis Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
- SEC Form 10-Q filed by Nexentis Technologies Inc.
- Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone
- Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX's Algorithm Platform MITOLINE™
- Nexentis Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form EFFECT filed by Nexentis Technologies Inc.
- SEC Form S-3 filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders
- SEC Form 10-K filed by Nexentis Technologies Inc.